Spears Abacus Advisors LLC Catalent, Inc. Transaction History

Spears Abacus Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$31.86 - $67.26 $53,397 - $112,727	-1,676 Reduced 16.76%	8,326 $361,000
Q1 2023 May 15, 2023	SELL	$45.44 - $74.26 $145,680 - $238,077	-3,206 Reduced 24.27%	10,002 $657,000
Q4 2022 Feb 13, 2023	BUY	$41.39 - $81.0 $546,679 - $1.07 Million	13,208 New	13,208 $594,000
Q4 2020 Feb 12, 2021	SELL	$85.88 - $105.36 $267,086 - $327,669	-3,110 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$72.74 - $92.5 $67,211 - $85,470	-924 Reduced 22.91%	3,110 $266,000
Q2 2020 Aug 12, 2020	SELL	$48.02 - $79.04 $5,042 - $8,299	-105 Reduced 2.54%	4,034 $296,000
Q1 2020 May 15, 2020	BUY	$36.95 - $62.95 $152,936 - $260,550	4,139 New	4,139 $215,000

511

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Spears Abacus Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Spears Abacus Advisors LLC with notifications on news.